This is a statement made under Section 54 of the UK Modern Slavery Act 2015. It seeks to outline the steps taken by Cytek Biosciences, Inc. and our subsidiaries (“Cytek”) to assess our susceptibility to modern slavery risks, to review our due diligence and risk assessment practices, and to continue to ensure that modern slavery and human trafficking is not taking place in any of our supply chains.  

The term "modern slavery" is used in this statement to describe a broad range of situations. These include, but are not limited to, slavery, servitude, forced marriage, forced labor, debt bondage, deceptive recruiting practices and child labor. It also includes the withholding or seizure of personal identification documentation. "Human trafficking" occurs when a person arranges or facilitates the travel of another person with a view to the other person being exploited. 

This statement sets out the steps taken to prevent modern slavery by all entities within our group that trigger the reporting requirements of the UK Modern Slavery Act 2015. 

 

OUR STRUCTURE

Cytek is a biotechnology company specializing in cancer and cell biology research. We specialise in the development, production, sales and after-sales service of advanced flow cytometry instrumentation, reagents, and software for use in academic research, clinical research and drug discovery. Our products enable researchers to analyze and sort cells with high precision and speed, providing valuable insights into diseases and potential treatments. 

We are committed to improving the world through scientific innovation and to providing solutions which allow scientists and researchers to obtain high-quality data. Our products are used across many world-leading pharmaceutical companies, CRO firms and academic research institutions across the world.  

We are headquartered in the United States and currently have operations in the United States, the Netherlands, China and Japan.

OUR SUPPLY CHAINS

We operate in the biotechnology industry. Our supply chain is predominantly manufacturing based, and our manufacturing operations are located in the United States (Fremont and San Diego, California) and in Wuxi, China. We have a complex supply chain which reflects the complex nature of the parts we require for the instruments we create. We have several long-term supply agreements in place with our suppliers.  

 

OUR POLICIES

We have a Code of Business Conduct and Ethics (the "Code") which sets out the standards and business practices which we expect our employees and other connected parties (e.g., contractors) to abide by. The Code ensures that employees are aware of the high standards of honest and ethical conduct that are required of them.  

Another pillar of our Code is legal compliance. We expect our employees, and our business as a whole, to cooperate within all local, national and international laws and authorities, and to operate within the relevant local laws at all times. We have a strict no-tolerance policy to breaches of the law and by extension, our Code.  

We also have a whistleblower policy through which employees can make disclosures about conduct which is violation of our Code or any laws. The whistleblower policy is also applicable to other parties, such as consultants or vendors. Concerns can be submitted on an anonymous and confidential basis via a toll-free number or filling out an internet-based form. Both services are available on a 24/7 basis.   

 

DUE DILIGENCE PROCESSES AND RISK MANAGEMENT

Where applicable, we require our suppliers to represent their compliance with local laws and regulations, including all employment-related laws. Most of our agreements with suppliers contain audit rights in our favour. To date, we are not aware of any modern slavery or forced labor issues.   

 

TRAINING 

We currently do not have any specific training in relation to modern slavery; however, all of our employees receive training regarding, and are required to acknowledge and agree to be bound by, our Code.  

 

DECLARATION 

This statement is made pursuant to section 54(1) of the Modern Slavery Act 2015 and has been approved by Cytek Biosciences, Inc., and is signed below by Cytek’s Chief Executive Officer, Chairman of the Board, and Director of Cytek Biosciences B.V. as of April 20, 2023. It will be reviewed and updated on an annual basis as necessary.  

  

Wenbin Jiang 

Chief Executive Officer, Cytek Biosciences, Inc.

Director, Cytek Biosciences B.V.